MRK vs RTX
MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda. RTX: RTX is a global leader in aerospace and defense, supplying critical technology ranging from commercial aircraft engines to advanced missile defense systems.
Side-by-side fundamentals
| Metric | MRK | RTX | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $130.48 | $209.16 | |
| Market cap as of 2026-07-25 | $323.6B | $286.6B | |
| P/E as of 2026-07-25 | 36.22 | 37.03 | MRK lower |
| PEG as of 2026-07-25 | 4.34 | 3.42 | RTX lower |
| Net margin as of 2026-07-25 | +13.6% | +8.3% | MRK higher |
| Gross margin as of 2026-07-25 | +78.1% | +20.4% | MRK higher |
| Operating margin as of 2026-07-25 | +18.2% | +11.2% | MRK higher |
| ROE as of 2026-07-25 | +17.9% | +11.8% | MRK higher |
| ROA as of 2026-07-25 | +7.0% | +4.5% | MRK higher |
| Debt / equity as of 2026-07-25 | 1.07 | 0.56 | RTX lower |
| Revenue growth (YoY) as of 2026-07-25 | +2.9% | +11.8% | RTX higher |
| Revenue CAGR (3y) SEC XBRL | +3.1% | +9.7% | RTX higher |
| Dividend yield as of 2026-07-25 | +2.6% | +1.4% | MRK higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-25 | 0.21 | 0.29 | |
| 1-year return as of 2026-07-23 close | +55.8% | +37.1% | MRK higher |
Fundamentals: Finnhub, as of 2026-07-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.